Genomic Medicine and Implications for Hepatocellular Carcinoma Prevention and Therapy

Renumathy Dhanasekaran, Jean Charles Nault, Lewis Rowland Roberts, Jessica Zucman-Rossi

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

The pathogenesis of hepatocellular carcinoma (HCC) is poorly understood, but recent advances in genomics have increased our understanding of the mechanisms by which hepatitis B virus, hepatitis C virus, alcohol, fatty liver disease, and other environmental factors, such as aflatoxin, cause liver cancer. Genetic analyses of liver tissues from patients have provided important information about tumor initiation and progression. Findings from these studies can potentially be used to individualize the management of HCC. In addition to sorafenib, other multi-kinase inhibitors have been approved recently for treatment of HCC, and the preliminary success of immunotherapy has raised hopes. Continued progress in genomic medicine could improve classification of HCCs based on their molecular features and lead to new treatments for patients with liver cancer.

Original languageEnglish (US)
Pages (from-to)492-509
Number of pages18
JournalGastroenterology
Volume156
Issue number2
DOIs
StatePublished - Jan 1 2019

Fingerprint

Hepatocellular Carcinoma
Medicine
Liver Neoplasms
Aflatoxins
Fatty Liver
Genomics
Hepatitis B virus
Hepacivirus
Immunotherapy
Liver Diseases
Phosphotransferases
Therapeutics
Alcohols
Liver
Neoplasms
sorafenib

Keywords

  • Epigenetics
  • HCC
  • Hepatitis
  • Immunotherapy
  • Tert

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology

Cite this

Genomic Medicine and Implications for Hepatocellular Carcinoma Prevention and Therapy. / Dhanasekaran, Renumathy; Nault, Jean Charles; Roberts, Lewis Rowland; Zucman-Rossi, Jessica.

In: Gastroenterology, Vol. 156, No. 2, 01.01.2019, p. 492-509.

Research output: Contribution to journalArticle

Dhanasekaran, Renumathy ; Nault, Jean Charles ; Roberts, Lewis Rowland ; Zucman-Rossi, Jessica. / Genomic Medicine and Implications for Hepatocellular Carcinoma Prevention and Therapy. In: Gastroenterology. 2019 ; Vol. 156, No. 2. pp. 492-509.
@article{9a761b96909c4ddd9450fe2253dec072,
title = "Genomic Medicine and Implications for Hepatocellular Carcinoma Prevention and Therapy",
abstract = "The pathogenesis of hepatocellular carcinoma (HCC) is poorly understood, but recent advances in genomics have increased our understanding of the mechanisms by which hepatitis B virus, hepatitis C virus, alcohol, fatty liver disease, and other environmental factors, such as aflatoxin, cause liver cancer. Genetic analyses of liver tissues from patients have provided important information about tumor initiation and progression. Findings from these studies can potentially be used to individualize the management of HCC. In addition to sorafenib, other multi-kinase inhibitors have been approved recently for treatment of HCC, and the preliminary success of immunotherapy has raised hopes. Continued progress in genomic medicine could improve classification of HCCs based on their molecular features and lead to new treatments for patients with liver cancer.",
keywords = "Epigenetics, HCC, Hepatitis, Immunotherapy, Tert",
author = "Renumathy Dhanasekaran and Nault, {Jean Charles} and Roberts, {Lewis Rowland} and Jessica Zucman-Rossi",
year = "2019",
month = "1",
day = "1",
doi = "10.1053/j.gastro.2018.11.001",
language = "English (US)",
volume = "156",
pages = "492--509",
journal = "Gastroenterology",
issn = "0016-5085",
publisher = "W.B. Saunders Ltd",
number = "2",

}

TY - JOUR

T1 - Genomic Medicine and Implications for Hepatocellular Carcinoma Prevention and Therapy

AU - Dhanasekaran, Renumathy

AU - Nault, Jean Charles

AU - Roberts, Lewis Rowland

AU - Zucman-Rossi, Jessica

PY - 2019/1/1

Y1 - 2019/1/1

N2 - The pathogenesis of hepatocellular carcinoma (HCC) is poorly understood, but recent advances in genomics have increased our understanding of the mechanisms by which hepatitis B virus, hepatitis C virus, alcohol, fatty liver disease, and other environmental factors, such as aflatoxin, cause liver cancer. Genetic analyses of liver tissues from patients have provided important information about tumor initiation and progression. Findings from these studies can potentially be used to individualize the management of HCC. In addition to sorafenib, other multi-kinase inhibitors have been approved recently for treatment of HCC, and the preliminary success of immunotherapy has raised hopes. Continued progress in genomic medicine could improve classification of HCCs based on their molecular features and lead to new treatments for patients with liver cancer.

AB - The pathogenesis of hepatocellular carcinoma (HCC) is poorly understood, but recent advances in genomics have increased our understanding of the mechanisms by which hepatitis B virus, hepatitis C virus, alcohol, fatty liver disease, and other environmental factors, such as aflatoxin, cause liver cancer. Genetic analyses of liver tissues from patients have provided important information about tumor initiation and progression. Findings from these studies can potentially be used to individualize the management of HCC. In addition to sorafenib, other multi-kinase inhibitors have been approved recently for treatment of HCC, and the preliminary success of immunotherapy has raised hopes. Continued progress in genomic medicine could improve classification of HCCs based on their molecular features and lead to new treatments for patients with liver cancer.

KW - Epigenetics

KW - HCC

KW - Hepatitis

KW - Immunotherapy

KW - Tert

UR - http://www.scopus.com/inward/record.url?scp=85060078051&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060078051&partnerID=8YFLogxK

U2 - 10.1053/j.gastro.2018.11.001

DO - 10.1053/j.gastro.2018.11.001

M3 - Article

C2 - 30404026

AN - SCOPUS:85060078051

VL - 156

SP - 492

EP - 509

JO - Gastroenterology

JF - Gastroenterology

SN - 0016-5085

IS - 2

ER -